Allergan and Editas Medicine Initiate the Brilliance Phase 1|2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

Source :: Plus Company Updates. July 26, 2019
Publication Year :: 2019
Abstract: Massachusetts: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Subjects :: Allergan PLC -- Product development
Clinical trials
Pharmaceutical industry -- Product development
Blindness
Genetic research
Genes
Genetic disorders
Genomics
General interest
News, opinion and commentary

Tools